Shopping Cart 0
Cart Subtotal
USD 0

Traumatic Brain Injury - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Traumatic Brain Injury-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury-Pipeline Review, H2 2018, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.

Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 10, 63 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.

Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Traumatic Brain Injury-Overview 6

Traumatic Brain Injury-Therapeutics Development 7

Traumatic Brain Injury-Therapeutics Assessment 20

Traumatic Brain Injury-Companies Involved in Therapeutics Development 32

Traumatic Brain Injury-Drug Profiles 51

Traumatic Brain Injury-Dormant Projects 279

Traumatic Brain Injury-Discontinued Products 283

Traumatic Brain Injury-Product Development Milestones 284

Appendix 295


List Of Figure

List of Figures

Number of Products under Development for Traumatic Brain Injury, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Traumatic Brain Injury, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Traumatic Brain Injury-Pipeline by ALSP Inc, H2 2018

Traumatic Brain Injury-Pipeline by Amarantus Bioscience Holdings Inc, H2 2018

Traumatic Brain Injury-Pipeline by Aptinyx Inc, H2 2018

Traumatic Brain Injury-Pipeline by Athersys Inc, H2 2018

Traumatic Brain Injury-Pipeline by Avanir Pharmaceuticals Inc, H2 2018

Traumatic Brain Injury-Pipeline by Biogen Inc, H2 2018

Traumatic Brain Injury-Pipeline by CalciMedica Inc, H2 2018

Traumatic Brain Injury-Pipeline by Cantex Pharmaceuticals Inc, H2 2018

Traumatic Brain Injury-Pipeline by Cognosci Inc, H2 2018

Traumatic Brain Injury-Pipeline by Complement Pharma BV, H2 2018

Traumatic Brain Injury-Pipeline by Eisai Co Ltd, H2 2018

Traumatic Brain Injury-Pipeline by Epigen Biosciences Inc, H2 2018

Traumatic Brain Injury-Pipeline by Eustralis Pharmaceuticals Ltd, H2 2018

Traumatic Brain Injury-Pipeline by Hoverink Biotechnologies Inc, H2 2018

Traumatic Brain Injury-Pipeline by Intellect Neurosciences Inc, H2 2018

Traumatic Brain Injury-Pipeline by International Stem Cell Corp, H2 2018

Traumatic Brain Injury-Pipeline by Ischemix Inc, H2 2018

Traumatic Brain Injury-Pipeline by JT Pharmaceuticals Inc, H2 2018

Traumatic Brain Injury-Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Traumatic Brain Injury-Pipeline by Levolta Pharmaceuticals Inc, H2 2018

Traumatic Brain Injury-Pipeline by Lixte Biotechnology Holdings Inc, H2 2018

Traumatic Brain Injury-Pipeline by Mapreg SAS, H2 2018

Traumatic Brain Injury-Pipeline by Neuralstem Inc, H2 2018

Traumatic Brain Injury-Pipeline by Neuren Pharmaceuticals Ltd, H2 2018

Traumatic Brain Injury-Pipeline by Neurofx Inc, H2 2018

Traumatic Brain Injury-Pipeline by NeuroNascent Inc, H2 2018

Traumatic Brain Injury-Pipeline by NeuroVive Pharmaceutical AB, H2 2018

Traumatic Brain Injury-Pipeline by New World Laboratories Inc, H2 2018

Traumatic Brain Injury-Pipeline by NoNO Inc, H2 2018

Traumatic Brain Injury-Pipeline by Noxopharm Ltd, H2 2018

Traumatic Brain Injury-Pipeline by NuvOx Pharma LLC, H2 2018

Traumatic Brain Injury-Pipeline by Oxeia Biopharmaceuticals Inc, H2 2018

Traumatic Brain Injury-Pipeline by Prevacus Inc, H2 2018

Traumatic Brain Injury-Pipeline by QR Pharma Inc, H2 2018

Traumatic Brain Injury-Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2018

Traumatic Brain Injury-Pipeline by Resolys Bio Inc, H2 2018

Traumatic Brain Injury-Pipeline by Rubicon Biotechnology Inc, H2 2018

Traumatic Brain Injury-Pipeline by Sage Therapeutics Inc, H2 2018

Traumatic Brain Injury-Pipeline by SanBio Inc, H2 2018

Traumatic Brain Injury-Pipeline by Scythian Biosciences Corp, H2 2018

Traumatic Brain Injury-Pipeline by Silver Creek Pharmaceuticals Inc, H2 2018

Traumatic Brain Injury-Pipeline by STATegics Inc, H2 2018

Traumatic Brain Injury-Pipeline by Stemedica Cell Technologies Inc, H2 2018

Traumatic Brain Injury-Pipeline by SynZyme Technologies LLC, H2 2018

Traumatic Brain Injury-Pipeline by Tetra Discovery Partners LLC, H2 2018

Traumatic Brain Injury-Pipeline by Therapix Biosciences Ltd, H2 2018

Traumatic Brain Injury-Pipeline by Tiziana Life Sciences Plc, H2 2018

Traumatic Brain Injury-Pipeline by vasopharm GmbH, H2 2018

Traumatic Brain Injury-Pipeline by VG Life Sciences Inc, H2 2018

Traumatic Brain Injury-Dormant Projects, H2 2018

Traumatic Brain Injury-Dormant Projects, H2 2018 (Contd..1), H2 2018

Traumatic Brain Injury-Dormant Projects, H2 2018 (Contd..2), H2 2018

Traumatic Brain Injury-Dormant Projects, H2 2018 (Contd..3), H2 2018

Traumatic Brain Injury-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Traumatic Brain Injury Therapeutic Products under Development, Key Players in Traumatic Brain Injury Therapeutics, Traumatic Brain Injury Pipeline Overview, Traumatic Brain Injury Pipeline, Traumatic Brain Injury Pipeline Assessment


Companies

ALSP Inc

Amarantus Bioscience Holdings Inc

Aptinyx Inc

Athersys Inc

Avanir Pharmaceuticals Inc

Biogen Inc

CalciMedica Inc

Cantex Pharmaceuticals Inc

Cognosci Inc

Complement Pharma BV

Eisai Co Ltd

Epigen Biosciences Inc

Eustralis Pharmaceuticals Ltd

Hoverink Biotechnologies Inc

Intellect Neurosciences Inc

International Stem Cell Corp

Ischemix Inc

JT Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

Levolta Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

Mapreg SAS

Neuralstem Inc

Neuren Pharmaceuticals Ltd

Neurofx Inc

NeuroNascent Inc

NeuroVive Pharmaceutical AB

New World Laboratories Inc

NoNO Inc

Noxopharm Ltd

NuvOx Pharma LLC

Oxeia Biopharmaceuticals Inc

Prevacus Inc

QR Pharma Inc

RegeneRx Biopharmaceuticals Inc

Resolys Bio Inc

Rubicon Biotechnology Inc

Sage Therapeutics Inc

SanBio Inc

Scythian Biosciences Corp

Silver Creek Pharmaceuticals Inc

STATegics Inc

Stemedica Cell Technologies Inc

SynZyme Technologies LLC

Tetra Discovery Partners LLC

Therapix Biosciences Ltd

Tiziana Life Sciences Plc

vasopharm GmbH

VG Life Sciences Inc